FY2023 · ended Dec 31, 2023 · Revenue $0 · Filed Feb 1, 2024
Oruka Therapeutics, Inc. (ORKA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$88.4 million. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $2.5 million in total debt.
Revenue
$0
Net income
$-105.43M
-25.9% vs prior year
Operating cash flow (TTM)
$-100.92M
-3.3% vs year-ago TTM
Free cash flow (TTM)
$-101.15M
EPS
$-3.87
-945.9% vs prior year
Dividend per share
None
Shares outstanding
49.54M
+32.3% vs prior year
Net cash
$1.12B
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORKA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 907654
- Former names
- ARCA biopharma, Inc. (until Aug 30, 2024); NUVELO INC (until Jan 27, 2009); HYSEQ INC (until Jan 28, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$122.1M | -$88.1M | -$7.3M | -$10.6M | -$19.3M |
| Net income | -$105.4M | -$83.7M | -$5.3M | -$9.9M | -$19.3M |
| Diluted EPS | — | -$3.87 | -$0.37 | -$0.69 | — |
| Operating cash flow | -$88.2M | -$57.8M | -$5.0M | -$10.9M | -$18.8M |
| Free cash flow | -$88.4M | -$58.0M | -$5.0M | -$10.9M | -$18.8M |
| Total assets | $488.6M | $396.0M | $37.9M | $43.1M | $54.9M |
| Total liabilities | $16.7M | $13.8M | $841,000 | $1.4M | $3.9M |
| Stockholders' equity | $471.9M | $382.2M | $37.0M | $41.7M | $51.0M |
| Cash and investments | $479.6M | $393.7M | $37.4M | $42.4M | $53.4M |
| Total debt | $1.9M | $968,000 | $280,000 | $383,000 | $483,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Other events
|
Jun 1, 2026 | May 29, 2026 |
All 1001 Oruka Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.